AR104262A1 - Derivados de cromeno como inhibidores de las fosfoinositido-3 quinasas - Google Patents
Derivados de cromeno como inhibidores de las fosfoinositido-3 quinasasInfo
- Publication number
- AR104262A1 AR104262A1 ARP160101019A ARP160101019A AR104262A1 AR 104262 A1 AR104262 A1 AR 104262A1 AR P160101019 A ARP160101019 A AR P160101019A AR P160101019 A ARP160101019 A AR P160101019A AR 104262 A1 AR104262 A1 AR 104262A1
- Authority
- AR
- Argentina
- Prior art keywords
- phosfoinositido
- kinases
- inhibitors
- substituted
- chromene derivatives
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Reivindicación 1: Un compuesto caracterizado porque es de fórmula (1) donde: R¹ y R² son ambos H o se combinan para formar un grupo oxo (=O); R³ y R⁴, que pueden ser iguales o diferentes, en cada caso se selecciona en forma independiente entre el grupo formado por: H, C₁₋₆ alquilo y C₁₋₆ haloalquilo; R⁵ se puede seleccionar entre el grupo formado por arilo sustituido o no sustituido, y heteroarilo sustituido o no sustituido; Z, está ausente o NH; Cy es un heteroarilo sustituido o no sustituido; o su sal farmacéuticamente aceptable.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15163902 | 2015-04-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR104262A1 true AR104262A1 (es) | 2017-07-05 |
Family
ID=52991512
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP160101019A AR104262A1 (es) | 2015-04-16 | 2016-04-14 | Derivados de cromeno como inhibidores de las fosfoinositido-3 quinasas |
Country Status (12)
Country | Link |
---|---|
US (1) | US9968604B2 (es) |
EP (1) | EP3283481B1 (es) |
KR (1) | KR20170137127A (es) |
CN (1) | CN107454902B (es) |
AR (1) | AR104262A1 (es) |
BR (1) | BR112017022158B1 (es) |
CA (1) | CA2982631A1 (es) |
HK (1) | HK1246779A1 (es) |
MX (1) | MX2017013137A (es) |
RU (1) | RU2722383C2 (es) |
TR (1) | TR201907614T4 (es) |
WO (1) | WO2016166239A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT3691620T (pt) | 2017-10-05 | 2022-10-06 | Fulcrum Therapeutics Inc | Os inibidores da quinase p38 reduzem a expressão de dux4 e genes a jusante para o tratamento de fshd |
US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
HUE056615T2 (hu) * | 2017-10-18 | 2022-02-28 | Incyte Corp | Tercier hidroxicsoportokkal szubsztituált kondenzált imidazol-származékok mint PI3K-gamma inhibitorok |
CN117304157A (zh) | 2018-02-27 | 2023-12-29 | 阿塔克斯生物制药有限公司 | 作为tcr-nck相互作用的抑制剂的色烯衍生物 |
WO2020051169A1 (en) | 2018-09-05 | 2020-03-12 | Incyte Corporation | Crystalline forms of a phosphoinositide 3-kinase (pi3k) inhibitor |
MA55479A (fr) | 2019-04-04 | 2022-02-09 | Chiesi Farm Spa | Dérivés d'isochromène utilisés en tant qu'inhibiteurs de phosphoinositide 3-kinases |
CN111346095B (zh) * | 2020-03-14 | 2021-06-08 | 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 | 用于治疗神经外科术后头痛的药物制剂 |
CN114891005B (zh) * | 2022-03-30 | 2024-01-19 | 武汉九州钰民医药科技有限公司 | 一种乌帕利斯对甲苯磺酸盐的制备工艺 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2772761B1 (fr) | 1997-12-23 | 2000-05-26 | Lipha | Nouveaux derives de n-phenylamide et n-pyridylamide, leur procede de preparation et compositions pharmaceutiques les contenant |
FR2797874B1 (fr) | 1999-08-27 | 2002-03-29 | Adir | Nouveaux derives de la pyridine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
EP1471064A4 (en) | 2002-01-11 | 2005-04-27 | Takeda Pharmaceutical | Cumarin derivatives, process for their preparation and their use |
DE102007018072A1 (de) | 2007-04-17 | 2008-10-30 | Volkswagen Ag | Anzeigeeinrichtung für ein Fahrzeug zum Anzeigen von den Betrieb des Fahrzeugs betreffende Informationen und Verfahren zum Anzeigen dieser Informationen |
MX352661B (es) * | 2009-11-05 | 2017-12-04 | Rhizen Pharmaceuticals S A Star | Moduladores novedosos de benzopiran cinasa. |
ES2379242B1 (es) * | 2010-09-28 | 2013-03-04 | Consejo Superior De Investigaciones Científicas (Csic) | Derivados de cromeno. |
CN102746281B (zh) * | 2011-04-22 | 2015-01-14 | 四川大学 | 4-1,2,3-三氮唑-香豆素衍生物及其制备方法和用途 |
PL2705029T4 (pl) * | 2011-05-04 | 2019-04-30 | Rhizen Pharmaceuticals S.A. | Nowe związki jako modulatory kinaz białkowych |
EP2968345B1 (en) | 2013-03-13 | 2017-12-13 | The Regents of The University of Michigan | Dual mek/pi3k inhibitors and their application in the treatment of cancer diseases |
TWI672297B (zh) | 2013-12-18 | 2019-09-21 | 義大利商吉斯藥品公司 | 作為磷脂肌醇-3-激酶抑制劑之異唏衍生物 |
-
2016
- 2016-03-24 US US15/079,740 patent/US9968604B2/en active Active
- 2016-04-14 KR KR1020177031451A patent/KR20170137127A/ko unknown
- 2016-04-14 MX MX2017013137A patent/MX2017013137A/es active IP Right Grant
- 2016-04-14 CA CA2982631A patent/CA2982631A1/en not_active Abandoned
- 2016-04-14 RU RU2017134899A patent/RU2722383C2/ru active
- 2016-04-14 TR TR2019/07614T patent/TR201907614T4/tr unknown
- 2016-04-14 BR BR112017022158-6A patent/BR112017022158B1/pt active IP Right Grant
- 2016-04-14 WO PCT/EP2016/058261 patent/WO2016166239A1/en active Application Filing
- 2016-04-14 EP EP16720054.2A patent/EP3283481B1/en active Active
- 2016-04-14 CN CN201680021995.7A patent/CN107454902B/zh not_active Expired - Fee Related
- 2016-04-14 AR ARP160101019A patent/AR104262A1/es unknown
-
2018
- 2018-05-09 HK HK18106024.7A patent/HK1246779A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
RU2017134899A (ru) | 2019-05-16 |
BR112017022158A2 (pt) | 2018-07-03 |
MX2017013137A (es) | 2018-02-21 |
EP3283481A1 (en) | 2018-02-21 |
US9968604B2 (en) | 2018-05-15 |
WO2016166239A1 (en) | 2016-10-20 |
RU2017134899A3 (es) | 2019-06-17 |
KR20170137127A (ko) | 2017-12-12 |
BR112017022158B1 (pt) | 2024-01-09 |
RU2722383C2 (ru) | 2020-05-29 |
CA2982631A1 (en) | 2016-10-20 |
TR201907614T4 (tr) | 2019-06-21 |
CN107454902B (zh) | 2020-09-15 |
US20160303123A1 (en) | 2016-10-20 |
CN107454902A (zh) | 2017-12-08 |
EP3283481B1 (en) | 2019-03-13 |
HK1246779A1 (zh) | 2018-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR104262A1 (es) | Derivados de cromeno como inhibidores de las fosfoinositido-3 quinasas | |
EA201792519A1 (ru) | Противогрибковые соединения | |
EA201892710A1 (ru) | Карбамоилоксиметилтриазолциклогексильные кислоты в качестве антагонистов lpa | |
AR096246A1 (es) | Derivados de benzimidazol como inhibidores de bromodominio | |
AR092349A1 (es) | Imidazotriazincarbonitrilos utiles como inhibidores de quinasa | |
EA201991197A1 (ru) | БЕНЗИМИДАЗОЛЬНЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ c-Kit | |
AR110405A1 (es) | Compuestos | |
AR095347A1 (es) | Compuestos orgánicos | |
AR077695A1 (es) | Derivados de pirimidina como inhibidores del factor ixa | |
AR099379A1 (es) | Compuestos tricíclicos como agentes antineoplásicos | |
EA202091505A1 (ru) | Триазолазолы циклогексильной кислоты в качестве антагонистов lpa | |
AR094313A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
AR101558A1 (es) | Difluoropirrolidinas como moduladores del receptor de orexina | |
AR108207A1 (es) | Derivados de pirrolo[2,3-c]piridina, inhibidores de bromodominios | |
PE20191245A1 (es) | Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim | |
BR112015019627A2 (pt) | amidas heterocíclicas como inibidores de quinases | |
CO2017001178A2 (es) | Derivado de piridona que tiene un grupo tetrahidropiranil metilo | |
PE20160689A1 (es) | Derivados del isocromeno como inhibidores de las fosfoinositido-3 quinasas | |
TW201613938A (en) | Selective inhibitors for protein kinases, a pharmaceutical composition and an use thereof | |
AR107170A1 (es) | Compuestos heterocíclicos tricíclicos condesados como inhibidores de integrasa del vih | |
BR112015018509A2 (pt) | compostos de imidazo piridina | |
EA201890626A1 (ru) | ЗАМЕЩЕННЫЕ 1,2-ДИГИДРО-3H-ПИРРОЛО[1,2-c]ИМИДАЗОЛ-3-ОНОВЫЕ АНТИБАКТЕРИАЛЬНЫЕ СОЕДИНЕНИЯ | |
AR088320A1 (es) | Derivados de isoindolinona y pirrolopiridinona como inhibidores de akt | |
BR112015029348A2 (pt) | inibidores da bace | |
AR089623A1 (es) | Inhibidores de iap |